A study undertaken in South Korea has shown that the viral load in asymptomatic COVID-19 patients is the same as in those who show symptoms of the disease and this could be contributing to the spread of the infection in populations.
Malara parasites showing artemisinin resistance previously seen in South-East Asia have recently emerged in areas of Rwanda in Sub-Saharan Africa. If the mutation causing resistance becomes prevalent across the continent it could have major public health impacts.
The Oxford vaccine, ChAdOx1 nCoV-19, has demonstrated strong immune responses to COVID-19 in patients, as well as a good safety profile, as the results of the Phase I/II trial are published.
In collaboration with the University of Southampton, Synairgen (both Southampton, UK) have announced positive results from their recent trial of SNG001, a novel protein based COVID-19 drug.
A research team from The Rosalind Franklin Institute, Diamond Light Source, The University of Oxford and Public Health England have engineered nanobodies from llama antibodies that show protective immune effects against SARS-CoV-2.
Differences in lung physiology and immune function in children may lie behind their decreased rates of symptomatic infections, hospitalization and death, according to a study from The University of Texas and Baylor College of Medicine (both TX, USA).
In a collaborative study between the University of South Florida (USF Health; FL, USA) and the University of Arizona College of Pharmacy (AZ, USA), several existing drugs have been identified as potential therapies for COVID-19.
Researchers have identified a specific change in the SARS-CoV-2 coronavirus spike protein that may increase its transmission, making it more infectious in cell culture.
Researchers at Cedars-Sinai Medical Center have discovered that SARS-CoV-2 can infect human myocardiocytes in vitro. COVID-19 infection can cause heart problems. This study demonstrates that this could be due to direct infection of myocardiocytes by the virus.
Researchers have accurately profiled the immune response to COVID-19 in critically ill patients, allowing them to identify six inflammatory molecules as potential targets for COVID-19 treatment.